

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

PERMANENT ADMINISTRATIVE ORDER

BP 59-2024

CHAPTER 855

BOARD OF PHARMACY

FILED

08/09/2024 11:24 AM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Amends Continuation of Therapy and adds new SARS-CoV-2 Antiviral protocol

EFFECTIVE DATE: 08/09/2024

AGENCY APPROVED DATE: 08/08/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

AMEND: 855-115-0345

NOTICE FILED DATE: 06/20/2024

RULE SUMMARY: Amends the Continuation of Therapy protocol by adding early refills of non-controlled opioid use disorder medications pursuant to directives of 2024 HB 4002 Sections 6,7, and 9. Adds new protocol SARS-CoV-2 Antiviral pursuant to 2024 SB 1506 to the protocol compendium.

CHANGES TO RULE:

855-115-0345

Services: Prescribing - Protocol Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol. ¶

(1) Continuation of therapy including emergency refills of insulin and early refills of opioid use disorder medications (v. 06/2024) ¶

(2) Conditions ¶

(a) Cough and cold symptom management ¶

(A) Benzonatate (v. 06/2021); ¶

(B) Short-acting beta agonists (v. 06/2021); ¶

(C) Intranasal corticosteroids (v. 06/2021); ¶

(b) Vulvovaginal candidiasis (VVC) (v. 06/2021); ¶

(c) COVID-19 Antigen Self-Test (v. 12/2021); ¶

(d) SARS-CoV-2 Antiviral (v. 08/2024) ¶

(3) Preventative care ¶

(a) Emergency Contraception (v. 06/2021); ¶

(b) Male and female condoms (v. 06/2021); ¶

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2024); ¶

(d) Travel Medications (v. 06/2024); ¶

(e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023); ¶

(f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023); ¶

(g) Contraception (v. 06/2023); ¶

(h) Sexually Transmitted Infections Post-exposure Prophylaxis (STI PEP) (v. 06/2024); ¶

(i) Short-acting Opioid Antagonists (v. 06/2024); and ¶

(j) Vaccines: ¶

- (A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 06/2024); ¶
- (B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 06/2024); ¶
- (C) Cholera (v. 02/2024); ¶
- (D) Coronavirus 2019 (v. 06/2024); ¶
- (E) Haemophilus Influenza type b (v. 06/2024); ¶
- (F) Hepatitis A containing vaccines (v. 02/2024); ¶
- (G) Hepatitis B containing vaccines (v. 02/2024); ¶
- (H) Human Papillomavirus (v. 02/2024); ¶
- (I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 06/2024); ¶
- (J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 02/2024); ¶
- (K) Japanese Encephalitis (v. 06/2024); ¶
- (L) Meningococcal containing vaccines (v. 06/2024); ¶
- (M) Measles Mumps & Rubella containing vaccines (v. 02/2024); ¶
- (N) Pneumococcal (v. 06/2024); ¶
- (O) Polio (v. 06/2024); ¶
- ¶
- (P) Rabies (v. 02/2024); ¶
- (Q) Respiratory Syncytial Virus (v. 06/2024); ¶
- (R) Tetanus Diphtheria containing vaccines (v. 06/2024); ¶
- (S) Typhoid (v. 02/2024); ¶
- (T) Varicella containing vaccines (v. 02/2024); ¶
- (U) Yellow fever (v. 06/2024); and ¶
- (V) Zoster (v. 02/2024). ¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205, 2024 HB 4002, 2024 SB 1506

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689, 2024 HB 4002, 2024 SB 1506